drug
Fluticasone Propionate Glenmark
Marketedupdated 3mo agoby Glenmark Pharmaceuticals Ltd
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 7- tagApproval30 co-mentions · 14 sources
- drugFLUTICASONE PROPIONATE26 co-mentions · 14 sources
- drugFlovent17 co-mentions · 14 sources
- drugFlovent HFA17 co-mentions · 14 sources
- drugCutivate17 co-mentions · 14 sources
- drugsalmeterol xinafoate2 co-mentions · 1 sources
- companyAurobindo Pharma Ltd2 co-mentions · 2 sources
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 11 approved and 14 investigational indications.
indications
investigational
Psoriasis
all catalysts(3)
Trials studying Fluticasone Propionate Glenmark
- phase3A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.
- phase4Dymista in Chinese Adolescents
- phase4A Bronchoscopy Study to Assess the Effects of Inhaled Corticosteroids on Adult Healthy Volunteers
- phase2Study on the Safety and Efficacy of PA9159 Inhalation Aerosol for the Treatment of Adult Bronchial Asthma
- phase2Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS).
- phase3A Study to Evaluate MK0476 and Fluticasone to Control Asthma in Patients With Mild Persistent Asthma (0476-910)
- phase4Effects of Mometasone Furoate Dry Powder Inhaler, Fluticasone Propionate, and Montelukast on Bone Mineral Density in Asthmatics (Study P03418)
- phase3Study of Inhaled Glucocorticosteroids/Long-Acting Bronchodilator Drugs in Subjects With Asthma That Have Been Taking Inhaled Glucocorticosteroids (Study P04705AM1)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Aug 26, 2026
6 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (118)
- Jan 6, 2041patentUS 11173259*PED
- Jan 6, 2041patentUS 11173259*PED
- Jan 6, 2041patentUS 11173259*PED
- Jan 6, 2041patentUS 11173259*PED
- Jan 6, 2041patentUS 11173259*PED
- Jan 6, 2041patentUS 11173259*PED
- Jan 6, 2041patentUS 11173259*PED
- Jul 6, 2040formulationUS 11173259
- Jul 6, 2040formulationUS 11173259
- Jul 6, 2040formulationUS 11173259
- Jul 6, 2040formulationUS 11173259
- Jul 6, 2040formulationUS 11173259
- Jul 6, 2040formulationUS 11173259
- Jul 6, 2040formulationUS 11173259
- Mar 26, 2040patentUS 11344685*PED
- Mar 26, 2040patentUS 11344685*PED
- Mar 26, 2040patentUS 11344685*PED
- Mar 26, 2040patentUS 11344685*PED
- Mar 26, 2040patentUS 11344685*PED
- Mar 26, 2040patentUS 11344685*PED
- Mar 26, 2040patentUS 11344685*PED
- Feb 20, 2040patentUS 11969544*PED
- Feb 20, 2040patentUS 11969544*PED
- Feb 20, 2040patentUS 11969544*PED
- Feb 20, 2040patentUS 11969544*PED
- Feb 20, 2040patentUS 11969544*PED
- Feb 20, 2040patentUS 11969544*PED
- Feb 20, 2040patentUS 11969544*PED
- Feb 20, 2040patentUS 11969544*PED
- Feb 20, 2040patentUS 11969544*PED
- Feb 20, 2040patentUS 11969544*PED
- Feb 20, 2040patentUS 11969544*PED
- Feb 20, 2040patentUS 11969544*PED
- Feb 20, 2040patentUS 11969544*PED
- Feb 20, 2040patentUS 11969544*PED
- Sep 26, 2039formulationUS 11344685
- Sep 26, 2039formulationUS 11344685
- Sep 26, 2039formulationUS 11344685
- Sep 26, 2039formulationUS 11344685
- Sep 26, 2039formulationUS 11344685
- Sep 26, 2039formulationUS 11344685
- Sep 26, 2039formulationUS 11344685
- Aug 20, 2039formulationUS 11969544
- Aug 20, 2039formulationUS 11969544
- Aug 20, 2039formulationUS 11969544
- Aug 20, 2039formulationUS 11969544
- Aug 20, 2039formulationUS 11969544
- Aug 20, 2039formulationUS 11969544
- Aug 20, 2039formulationUS 11969544
- Aug 20, 2039formulationUS 11969544
- Aug 20, 2039formulationUS 11969544
- Aug 20, 2039formulationUS 11969544
- Aug 20, 2039formulationUS 11969544
- Aug 20, 2039formulationUS 11969544
- Aug 20, 2039formulationUS 11969544
- Aug 20, 2039formulationUS 11969544
- Jun 14, 2036patentUS 10918816*PED
- Jun 14, 2036patentUS 10918816*PED
- Jun 14, 2036patentUS 10918816*PED
- Jun 14, 2036patentUS 10918816*PED
- Jun 14, 2036patentUS 10918816*PED
- Jun 14, 2036patentUS 10918816*PED
- Jun 14, 2036patentUS 10918816*PED
- Feb 23, 2036method-of-use (U-2133)US 11554229
- Dec 14, 2035formulationUS 10918816
- Dec 14, 2035formulationUS 10918816
- Dec 14, 2035formulationUS 10918816
- Dec 14, 2035formulationUS 10918816
- Dec 14, 2035formulationUS 10918816
- Dec 14, 2035formulationUS 10918816
- Dec 14, 2035formulationUS 10918816
- Apr 6, 2035patentUS 9066957*PED
- Apr 6, 2035patentUS 9066957*PED
- Apr 6, 2035patentUS 9066957*PED
- Apr 6, 2035patentUS 9066957*PED
- Apr 6, 2035patentUS 9066957*PED
- Apr 6, 2035patentUS 9066957*PED
- Apr 6, 2035patentUS 9415008*PED
- Apr 6, 2035patentUS 9415008*PED
- Oct 6, 2034formulationUS 9066957
- Oct 6, 2034formulationUS 9066957
- Oct 6, 2034formulationUS 9066957
- Oct 6, 2034formulationUS 9066957
- Oct 6, 2034formulationUS 9066957
- Oct 6, 2034formulationUS 9066957
- Oct 6, 2034formulationUS 9415008
- Oct 6, 2034formulationUS 9415008
- Aug 14, 2031patentUS 10195375*PED5.0y
- Aug 14, 2031patentUS 10195375*PED5.0y
- Aug 14, 2031patentUS 10195375*PED5.0y
- Aug 14, 2031patentUS 10195375*PED5.0y
- Aug 14, 2031patentUS 10195375*PED5.0y
- Aug 14, 2031patentUS 10195375*PED5.0y
- Aug 14, 2031patentUS 10195375*PED5.0y
- Aug 14, 2031patentUS 10195375*PED5.0y
- Aug 14, 2031patentUS 10195375*PED5.0y
- Aug 14, 2031patentUS 10195375*PED5.0y
- Aug 14, 2031patentUS 10195375*PED5.0y
- Aug 14, 2031patentUS 10195375*PED5.0y
- Aug 14, 2031patentUS 10195375*PED5.0y
- Aug 14, 2031patentUS 10195375*PED5.0y
- Apr 4, 2031method-of-use (U-2133)US 120832704.6y
- Feb 14, 2031formulationUS 101953754.5y
- Feb 14, 2031formulationUS 101953754.5y
- Feb 14, 2031formulationUS 101953754.5y
- Feb 14, 2031formulationUS 101953754.5y
- Feb 14, 2031formulationUS 101953754.5y
- Feb 14, 2031formulationUS 101953754.5y
- Feb 14, 2031formulationUS 101953754.5y
- Feb 14, 2031formulationUS 101953754.5y
- Feb 14, 2031formulationUS 101953754.5y
- Feb 14, 2031formulationUS 101953754.5y
- Feb 14, 2031formulationUS 101953754.5y
- Feb 14, 2031formulationUS 101953754.5y
- Feb 14, 2031formulationUS 101953754.5y
- Feb 14, 2031formulationUS 101953754.5y
- Aug 26, 2026patentUS 7500444*PED6d
- Aug 26, 2026patentUS 7500444*PED6d
FDA exclusivities (2)
- Mar 15, 2027I-940Indication (3y)207d
- Sep 20, 2026CGTCGT31d
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that